Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
about
Vaccines and antiviral drugs in pandemic preparednessInjectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)Current and future antiviral therapy of severe seasonal and avian influenzaA systematic analytic approach to pandemic influenza preparedness planning.Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferretsFatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemiaEfficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesWhat is the optimal therapy for patients with H5N1 influenza?Oseltamivir in the management of influenza.Pandemics, avian influenza A (H5N1), and a strategy for pharmacists.The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04.Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in miceAvian influenza: a pandemic waiting in the wings?Antiviral management of seasonal and pandemic influenza.Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.Avian influenza virus (H5N1): a threat to human health.The role of oseltamivir in the treatment and prevention of influenza in children.An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infectionPathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus sheddingInduction of long-term protective immune responses by influenza H5N1 virus-like particles.Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.Oseltamivir in human avian influenza infection.Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice.Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in miceNeuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virusAssessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferretsANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Peramivir for the treatment of influenza.Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication.The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesIntramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceAn antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza virusesEfficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.Virulence determinants of avian H5N1 influenza A virus in mammalian and avian hosts: role of the C-terminal ESEV motif in the viral NS1 protein.Animal Models for Influenza Virus Pathogenesis and Transmission.Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
P2860
Q22305646-3100631F-5D29-4A31-8049-1ACD1FBA250AQ24645944-01AB151F-4197-46E6-BAD7-73544DAB1A94Q24656164-DDCC4ADA-17D4-4A68-A4C5-38233C26D35FQ24811764-6096C617-452A-4CA6-B8F2-DFCAAADEF3E2Q27314689-EB183D3F-13AF-4C65-8201-6D6A57CDEF7DQ28262914-96901B21-FFB5-46C7-8D86-75220E2AD263Q28473051-A30F1223-FBA5-4E62-B31E-B31E1EF597C0Q28475630-B5C6FD05-AC02-442D-9E98-32406DFEBE8AQ30351736-15B288AA-59EB-4464-8608-78FE58304AD5Q30353151-9250DC69-51AD-4846-8017-87620981B986Q30353368-644C4C79-D26C-419D-B64B-8331DC3DC2EAQ30356532-199B3F7A-CD50-4D4B-B0EE-DC5B6AC10317Q30357432-5411F4A6-F397-4045-819B-2BFACBA09AE2Q30357794-536CD8C5-A58A-48DC-850D-2667951AD7D6Q30358735-D0F59527-C289-4B3F-8E59-4738740F1FF4Q30359842-B40DEC8F-2F4A-46F7-A16B-EF6F81A860EBQ30361041-66DDD377-ADD4-4B10-B684-D5B4707C4110Q30364977-430349EF-1E4F-4085-B4EE-FAB41DA0389DQ30371674-6A7A3D4A-5CAF-40AD-8C6F-CEE5BB336581Q30374356-A9AF4317-C780-4B5C-A379-85FD57E1959AQ30375255-731C4BAE-CB1A-42D2-88DA-8B8AFF56CF0DQ30376004-9AADE64D-D039-4515-B050-74689A0A0FEFQ30386487-A3496167-9490-4752-BBF3-720AD3BD8958Q30391956-FC79DA18-DAEA-4E33-AE77-641E8AA34314Q30394897-98C5C62B-EF75-4C6D-83C8-DBD1B0CA5B12Q30400058-39E25368-BC0E-4A1E-8865-2EE090A8EEEBQ30403382-BF775FD2-B769-4BB6-8B98-B197D4AA2B1FQ30404586-04C44D60-F468-4796-8710-5472DAB169E8Q30413154-6DDE94C6-66DC-42BA-B672-A07151A8AC5AQ30482353-F65A5779-031C-4F45-89F7-A749365D39F6Q30625335-CB2B8564-EA3E-4E5A-A245-8A888A63ED08Q33455759-4A16776C-A9EB-45BE-A8DB-BE3D590B749BQ33614501-1AB7173D-1724-433E-9401-3F4AA362FA60Q33639979-DAB4A1AC-50FE-407E-959E-BEA3DA21E644Q33761451-555CDBE8-D0DD-4EA1-9F47-A83877F629FCQ34046083-5137DB59-DD1A-46D4-A68E-BF3D2D582D82Q34058036-53141958-FACB-45C1-8D08-C9BF36E0EE3BQ34178292-E970739E-47D8-4418-8223-B4E62A47DB2CQ34714853-20767E75-C8E1-4EE8-BCCF-DB08173F169BQ35076802-34FA5AFA-507B-4915-A5ED-5279DB2B4BBF
P2860
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@ast
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@en
type
label
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@ast
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@en
prefLabel
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@ast
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@en
P50
P356
P1476
Virulence may determine the ne ...... 03/04 influenza virus in mice.
@en
P2093
Hui-Ling Yen
P304
P356
10.1086/432008
P407
P577
2005-07-15T00:00:00Z